Barr Joins Challenge To Zyprexa Patent

Law360, New York (December 3, 2004, 12:00 AM EST) -- Three years after Barr Laboratories Inc. successfully challenged the patent on Eli Lilly’s blockbuster antidepressant Prozac, the company has set its sights on the patent for Lilly’s new top-selling drug, the anti-psychotic Zyprexa.

Lilly has filed another patent infringement lawsuit Barr, the fourth generic maker to challenge the patent on the blockbuster anti-psychotic drug Zyprexa, Barr confirmed.

Lilly, already entrenched in litigation against three other challengers to the patent, filed its lawsuit on Wednesday in the U.S. District Court for the Southern District of Indiana to...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.